Abstract: A means for substantially improving mitochondrial dysfunction is provided. An aspect of the present invention relates to an agent for improving mitochondrial dysfunction, having a compound represented by the following formula, a stereoisomer or a salt thereof, or a solvate thereof, as an active ingredient. Another aspect of the present invention relates to a medicament or a pharmaceutical composition having the aforementioned compound, a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active ingredient, for use in preventing or treating a disease or symptom caused by mitochondrial dysfunction.

Abstract: The present invention relates to a mitochondria-targeted lipid membrane structure encapsulating a nucleic acid represented by any of the following a) to d): a) an RNA comprising, in this order, a nucleotide sequence of a first mitochondrial tRNA, a nucleotide sequence of an mRNA encoding a target protein, and a nucleotide sequence of a second mitochondrial tRNA, wherein the nucleotide sequence of the mRNA has one or more UGAs as a tryptophan codon; b) a DNA comprising a nucleotide sequence of a promoter and a nucleotide sequence complementary to the RNA of a); c) an RNA comprising a nucleotide sequence of an mRNA encoding a target protein, and a nucleotide sequence of a poly(A) chain present at the 3? end side thereof, wherein the nucleotide sequence of the mRNA has one or more UGAs as a tryptophan codon, AUG as a start codon, and UAA as a stop codon; and d) a DNA comprising a nucleotide sequence of a promoter and a nucleotide sequence complementary to the RNA of c).

Abstract: A means for substantially improving mitochondrial dysfunction is provided. An aspect of the present invention relates to an agent for improving mitochondrial dysfunction, having a compound represented by the following formula, a stereoisomer or a salt thereof, or a solvate thereof, as an active ingredient. Another aspect of the present invention relates to a medicament or a pharmaceutical composition having the aforementioned compound, a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active ingredient, for use in preventing or treating a disease or symptom caused by mitochondrial dysfunction.

Abstract: The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.

Abstract: The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.

Abstract: The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.

Abstract: An information processing apparatus includes an obtaining unit configured to obtain information regarding a size of a display screen of a display terminal that displays reflow format document data including a font with a set font size, a determining unit configured to determine whether the size of the display screen obtained from the information differs from a predetermined size, a setting unit configured to, if determined that the size of the display screen differs from the predetermined size, set the font size to a size determined based on the set font size, the size of the display screen, and the predetermined size, and if not determined that the size of the display screen differs from the predetermined size, keep the font size at the set font size, and a controlling unit configured to control the display screen to display the font at the font size set by the setting unit.

Abstract: An apparatus includes a selection unit configured to select a target page from a plurality of pages having an object, a detection unit configured to detect a page having an object which fits in a margin area in which an object is not arranged in the selected target page from among pages following the target page, and a display unit configured to display the selected target page and the detected page.

Abstract: The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.

Abstract: In the case of disposing regions of various sizes within a page, many blank areas appear and a layout result that is visually attractive could not be obtained. Therefore the present invention determines the starting position of a new row or column, using the difference in sizes of the multiple regions disposed in each row or column.

Abstract: A printing apparatus that is configured to, in order to efficiently execute printing by suitably skipping a page that is not to be printed, receive information about an attribute of paper to be skipped without printing, and based on information about the received attribute, print a page that does not use paper having the attribute and skip printing of a page that uses paper having the attribute.

Abstract: An information processing apparatus includes an obtaining unit configured to obtain information regarding a size of a display screen of a display terminal that displays reflow format document data including a font with a set font size, a determining unit configured to determine whether the size of the display screen obtained from the information differs from a predetermined size, a setting unit configured to, if determined that the size of the display screen differs from the predetermined size, set the font size to a size determined based on the set font size, the size of the display screen, and the predetermined size, and if not determined that the size of the display screen differs from the predetermined size, keep the font size at the set font size, and a controlling unit configured to control the display screen to display the font at the font size set by the setting unit.

Abstract: An information processing apparatus performs a process of laying out sub-templates to a page to which a repeated page setting is not set. If all the sub-templates are not laid out in the page to which a repeated page setting is not set, the information processing apparatus repeatedly obtains pages to which the repeated page setting is set until all the sub-templates are laid out in the pages.

Abstract: Automatic layout processing includes determining an area size based on a vertical size of sub-templates aligned in a row direction and a horizontal size of sub-templates aligned in a column direction, and locating each sub-template in a corresponding area.

Abstract: A printing apparatus that is configured to, in order to efficiently execute printing by suitably skipping a page that is not to be printed, receive information about an attribute of paper to be skipped without printing, and based on information about the received attribute, print a page that does not use paper having the attribute and skip printing of a page that uses paper having the attribute.

Abstract: A document processing apparatus which performs layout processing using first and second pages having first and second regions respectively on which content data is arranged. An obtaining processor obtains the content data and a generating processor generates a new page based on the first page in a case where the obtained content data falls inside neither the first nor second region and the first region is larger than the second region, and generates the new page based on the second page in a case where the obtained content data falls inside neither the first nor second region and the second region is larger than the first region. An arranging processor arranges the content data in the first region in the first page, the second region in the second page, and a region in the new page generated by the generating processor.

Abstract: In an information processing method of registering a processing flow, which defines cooperation processing of a plurality of tasks, in a manner that the processing flow can be shared by a plurality of users, a new processing flow is registered in association with a first user in response to a registration request of the new processing flow from the first user. In this stage, parameters of a task cooperated in the new processing flow are altered based on parameter information corresponding to another user different from the first user. Then, the new processing flow, where parameters have been altered, is registered in association with said another user.

Abstract: An apparatus includes a selection unit configured to select a target page from a plurality of pages having an object, a detection unit configured to detect a page having an object which fits in a margin area in which an object is not arranged in the selected target page from among pages following the target page, and a display unit configured to display the selected target page and the detected page.

Abstract: An image-forming device comprises an identifier-storage unit for storing an identifier in correlation with one of a plurality of feeding units on which at least one sheet used for image-forming processing is loaded, a specification unit for specifying the feeding unit by using the identifier, and a usability-determination unit for determining whether use of the specified feeding unit is permitted, where the image-forming device forms an image by feeding the sheet from the specified feeding unit based on the determination result made by the usability-determination unit.

Abstract: The distances between adjacent objects on a document are extracted. Next, the plurality of extracted distances are grouped on the basis of a value based on the horizontal (lateral) position of a distance-adjustment graphical user interface; the plurality of distances are unified to a representative value based on the vertical position of the distance-adjustment graphical user interface. Next, the objects are rearranged (subjected to relayout) so that the distance between the adjacent objects on the document becomes the representative value.